secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2025-10-01T23:59:59+00:00
Accession:  0001628280-25-043293
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior proposes redomiciliation to Delaware via new US parent IPI
-------------------------------------------------------------------

- Each Indivior PLC share exchanged for one share of new Delaware corporation Indivior Pharmaceuticals, Inc. (IPI).
- Timeline: shareholder circular mid-Nov 2025, EGM early Dec 2025, effective late Jan 2026.
- Scheme requires approval by 75% in value and majority in number of shareholders voting at EGM.
- No additional equity raised; IPI stock will trade on Nasdaq under symbol INDV.
- Proposed change aims to expand US capital markets presence and simplify governance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000162828025043293/0001628280-25-043293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000162828025043293/indv-20251001.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-043293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer